CJ-2360 is a potent orally available ALK inhibitor active against wild-type ALK and multiple ALK mutants (including F1197M, G1269A, L1196M, S1206Y, and C1156Y), as well as exhibiting strong inhibitory activity against 468 kinases including LTK, MERTK, CLK1, DAPK1, and DAPK2.